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OBJECTIVES We sought to examine the interaction between renal function and amino-terminal pro-brain
natriuretic peptide (NT-proBNP) levels.
BACKGROUND The effects of renal insufficiency on NT-proBNP among patients with and without acute
congestive heart failure (CHF) are controversial. We examined the effects of kidney disease
on NT-proBNP–based CHF diagnosis and prognosis.
METHODS A total of 599 dyspneic patients with glomerular filtration rates (GFRs) as low as 14.8 ml/min
were analyzed. We used multivariate logistic regression to examine covariates associated with
NT-proBNP results and linear regression analysis to analyze associations between NT-proBNP
and GFR. Receiver-operating characteristic analysis determined the sensitivity and specificity of
NT-proBNP for CHF diagnosis. We also assessed 60-day mortality rates as a function of
NT-proBNP concentration.
RESULTS Glomerular filtration rates ranged from 15 ml/min/1.73 m2 to 252 ml/min/1.73m2. Renal
insufficiency was associated with risk factors for CHF, and patients with renal insufficiency were
more likely to have CHF (all p  0.003). Worse renal function was accompanied by cardiac
structural and functional abnormalities on echocardiography. We found that NT-proBNP and
GFR were inversely and independently related (p 0.001) and that NT-proBNP values of 450
pg/ml for patients ages50 years and900 pg/ml for patients50 years had a sensitivity of 85%
and a specificity of 88% for diagnosing acute CHF among subjects with GFR 60 ml/min/1.73
m2. Using a cut point of 1,200 pg/ml for subjects with GFR 60 ml/min/1.73 m2, we found
sensitivity and specificity to be 89% and 72%, respectively. We found that NT-proBNP was the
strongest overall independent risk factor for 60-day mortality (hazard ratio 1.57; 95% confidence
interval 1.2 to 2.0; p  0.0004) and remained so even in those with GFR 60 ml/min/1.73 m2
(hazard ratio 1.61; 95% confidence interval 1.14 to 2.26; p  0.006).
CONCLUSIONS The use of NT-proBNP testing is valuable for the evaluation of the dyspneic patient with
suspected CHF, irrespective of renal function. (J Am Coll Cardiol 2006;47:91–7) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.051by the American College of Cardiology Foundation
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nesting for amino-terminal pro-brain natriuretic peptide
NT-proBNP) is valuable for the assessment of dyspneic
atients presenting to the emergency department (ED) with
uspected acute congestive heart failure (CHF) (1–3).
hen testing a dyspneic patient with NT-proBNP or the
elated B-type natriuretic peptide (BNP), important con-
iderations are necessary, including knowledge of the pa-
ient’s renal function. Chronic kidney disease (CKD) is
ighly prevalent among patients with CHF; conversely,
any of the same factors that place an individual at risk for
From the *Department of Medicine, Massachusetts General Hospital and Harvard
edical School, Boston, Massachusetts; and the †Department of Preventive Medi-
ine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. The
RIDE study was an investigator-initiated trial, supported by Roche Diagnostics
Indianapolis, Indiana). Data collection, analysis, and interpretation, as well as
anuscript preparation, were performed by the PRIDE Study Group, Massachusetts
eneral Hospital, Boston, Massachusetts. Dr. Januzzi has received grant support,
peaking fees, and consulting income from Roche Diagnostics Inc., the sponsor of the
RIDE study.A
Manuscript received June 10, 2005; revised manuscript received August 4, 2005,
ccepted August 9, 2005.HF can have similarly detrimental effects on renal func-
ion. This intersection between cardiac and renal insuffi-
iencies—the so-called “cardio-renal” interaction (4–8)—is
ssociated with increased rates of morbidity and mortality in
atients so afflicted (5,6,8–15). It is not surprising therefore,
hat CKD affects the concentrations of both NT-proBNP
nd BNP; however, it is not yet clear whether this effect
eflects the increased release of the markers due to the
resence of cardiac disease in patients with CKD or due to
eductions in their clearance, as both markers may have a
egree of dependence on renal function for their removal
rom circulation (16–20).
Although the effect of declining renal function on BNP
as been examined previously (17,18), less is understood
egarding the effects of renal function on NT-proBNP levels
n patients both with and without CHF, and it has been
uggested the accuracy of NT-proBNP may be more vul-
erable than BNP to abnormalities in renal function (21).
ccordingly, we undertook the present analysis of partici-
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Renal Function and Natriuretic Peptides January 3, 2006:91–7ants from the ProBNP Investigation of Dyspnea in the
mergency Department (PRIDE) study (1) to better un-
erstand the relationship between renal function, NT-
roBNP levels, and CHF.
ETHODS
tudy sample. The institutional review board approved all
nvestigational procedures involved in this study. The
RIDE study was a prospective study of NT-proBNP
esting of 599 dyspneic patients presenting to the ED. The
etails of the PRIDE study have recently been described (1).
n brief, dyspneic patients in an urban ED with suspected
HF were evaluated for inclusion, including blinded assess-
ent of NT-proBNP, drawn at the time of inclusion.
mong the exclusion criteria for the PRIDE study was a
erum creatinine 2.5 mg/dl.
Using all information pertaining to the presentation,
ncluding ED records, hospital records (if applicable), re-
ults of diagnostic imaging and laboratory testing (save
T-proBNP values), primary care office notes, and the
esults of the 60-day follow-up phone call, a cardiologist
etermined the cause for each patient’s presentation. Of the
ubjects enrolled, 209 (35%) subjects were judged to have
cute CHF. In the initial PRIDE study report (1), it was
etermined that an NT-proBNP level 450 pg/ml for
atients 50 years of age and 900 pg/ml for those 50
ears of age was the most highly sensitive and specific for
he diagnosis of acute CHF in the entire cohort. The
anufacturer’s recommended cut points for excluding CHF
125 pg/ml for patients 75 years and 450 pg/ml for
atients 75 years) were useful with 99% negative predic-
ive value; however, we found that a single, age-independent
hreshold of 300 pg/ml was similarly useful for excluding
he CHF, with a negative predictive value of 99%.
lasma natriuretic peptide measurements. At the time of
atient enrollment, blood was collected into ethylene di-
mine tetraacetic acid-containing tubes. After collection,
he samples were processed and frozen at80°C for analysis
fter the PRIDE study was completed. We measured
T-proBNP using an automated, commercially available
mmunoassay (Elecsys ProBNP, Roche Diagnostics, India-
Abbreviations and Acronyms
BNP  B-type natriuretic peptide
CHF  congestive heart failure
CKD  chronic kidney disease
ED  emergency department
GFR  glomerular filtration rate
IQR  interquartile range
NT-proBNP  amino-terminal pro-brain natriuretic
peptide
PRIDE  ProBNP Investigation of Dyspnea in the
Emergency Department study
ROC  receiver-operating characteristicapolis, Indiana) using established methodology. The assay Kor NT-proBNP has 0.001% cross-reactivity with bioac-
ive BNP and an interassay coefficient of variation (CV) of
.9% for the analyses in the PRIDE study. In addition,
NP also was measured (ADVIA Centaur BNP, Bayer
iagnostics, Tarrytown, New York) on the 209 patients with
cute CHF using established methodology. This assay had a
V of 2.6% in the PRIDE study.
ssessment of renal function in the PRIDE study. For
he purposes of the present study, subjects in the PRIDE
tudy were grouped by their renal function. Using the
odified Diet in Renal Disease equation (22), we estimated
lomerular filtration rate (GFR).
tatistical analyses. Although the GFR distribution was
roken into categories for display purposes, all analyses were
ased on the original continuous distributions. Echocardi-
graphy results are presented for those with available data,
ncluding those without acute CHF. Associations between
aseline GFR and dichotomous patient characteristics (in-
luding available echocardiography data) were assessed us-
ng a logistic regression model, whereas continuous variables
ere assessed using the Kruskal-Wallis test.
Values for NT-proBNP and BNP (the latter only from
hose patients with acute CHF) were log-transformed to
chieve normality, and correlations between natriuretic pep-
ide levels and renal function were performed using Pear-
on’s correlation coefficient. In addition, multivariate linear
egression analysis analyzed the association between renal
unction and log-transformed NT-proBNP levels.
To evaluate the effects of renal function on NT-proBNP
evels in the presence and absence of CHF, as well as the
rognostic impact of NT-proBNP with respect to renal
unction, univariable and multivariable logistic and linear
egression analyses were performed. For the evaluation of
he effects of renal function on NT-proBNP, log-
ransformed NT-proBNP was used as the dependent vari-
ble. In the mortality analysis, 60-day vital status was the
ependent variable. Covariates that were strongly associated
ith the dependent variable in univariate analysis (p 0.10)
ere included in the multivariate analysis. All models were
tted, found to be appropriate, and tested for first-order
nteractions.
Statistical analyses were performed with the use of either
PSS (SPSS Inc., Chicago, Illinois) or STATA software
ersion 8SE (STATA Corp., College Station, Texas). A
wo-sided p value of 0.05 was considered significant.
eceiver-operating characteristic analyses. Receiver-
perating characteristic (ROC) analyses were performed
cross the ranges of GFR in the PRIDE study to assess
ptimal NT-proBNP cut points at different levels of renal
unction. For the purposes of ROC analyses, allowing for
ptimal power, we examined patients as a function of
ormal to mild (i.e., GFR  60 ml/min/1.73 m2) and
oderate-to-severe CKD (i.e., GFR  60 ml/min/1.73 m2).
eceiver-operating characteristic analyses were performed with
nalyse-it software (Analyse-it Software, Ltd., Leeds, United
ingdom).
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enal function and baseline clinical characteristics.
atients with a serum creatinine of 1.5 to 2.5 mg/dl
ccounted for 14.7% (n  73) of the total study sample of
99 subjects; however, the estimated GFR varied widely,
rom 14.8 ml/min/1.72 m2 to 252 ml/min/1.72 m2, and 206
atients (34%) had moderate-to-severe renal insufficiency
defined as a GFR 60 ml/min/1.73 m2). Across the range
f renal function in the PRIDE study, several important
ssociations with clinical factors were noted (Table 1). With
ecreasing renal function, patients were more likely to be
en (p  0.002); to have more prevalent risk factors for
HF, including advancing age (p  0.001); and to have
istories of atrial fibrillation, myocardial infarction, or
ypertension (all p  0.002). In addition, patients with
KD were more likely to have CHF either in the past
nd/or at the index presentation, and more likely to use
iuretics (all p  0.001). Among patients with acute CHF,
orse renal function also was associated with more severe
HF symptoms (p  0.001).
Because 140 of the study subjects underwent echocardi-
graphy as standard of care after their enrollment into the
RIDE study, we had an opportunity to perform an analysis
f the relationship between changes in renal function and
he prevalence of significant structural heart disease. Rela-
ive to the group as a whole, more patients with acute CHF
nderwent echocardiography, particularly in the range of
ild renal insufficiency. As demonstrated in Table 2, a
trong graded relationship between abnormalities in renal
unction and the presence of several cardiac structural and
unctional abnormalities was found; stratifying subjects as a
unction of GFR  or 60 ml/min/1.73m2 and diagnosis
r absence of CHF illustrates the effects of renal function on
he prevalence of structural heart disease in those with and
able 1. Clinical Characteristics of All Study Patients, Stratified
<30
(n  19)
ge, yrs (mean  SD) 78.0  7.6
ale gender 89%
revious CHF 89%
revious atrial fibrillation 16%
revious myocardial infarction 16%
iabetes mellitus 26%
ystemic hypertension 63%
oop diuretic therapy 74%
TnT, ng/ml (mean  SD) 0.20  0.36
reatinine, mg/dl (mean  SD) 2.21  .31
cute CHF 74%
YHA functional class (CHF patients only)
II (n  29) 5%
III (n  73) 19%
IV (n  107) 76%
HF  congestive heart failure; cTnT  troponin T; NYHA  New York Heartithout acute CHF. penal function and median NT-proBNP levels. In the
90 subjects without acute CHF in the PRIDE study,
edian values of NT-proBNP were significantly greater in
hose with worse renal function (p  0.001) (Fig. 1);
owever, the values often were well below the cut points for
cute CHF; as an example, among those subjects without
HF, with GFR 60 ml/min/1.73 m2 (n  78), 64% had
T-proBNP concentrations below the defined cut points
or ruling in CHF from the PRIDE study (1). In addition,
hose with acute CHF and worse renal function also
emonstrated significantly higher concentrations of NT-
roBNP compared with those with acute CHF and better
enal function (p  0.001) (Fig. 1).
Lastly, a similar inverse relationship was noted between
FR and median BNP levels in those with acute CHF with
edian BNP values observed in these CHF subjects of 175,
80, 412, and 524 pg/ml in categories of 90, 60 to 90, 30
o 59, and 30 ml/min/1.73 m2 (p  0.01) (Fig. 1).
ssessment of NT-proBNP, BNP, and renal function. With
ower GFR, log-transformed NT-proBNP levels increased
mong all patients in the study (r0.55, p 0.001) (Fig.
) and in those without acute CHF (r0.41; p 0.001).
n patients with acute CHF, this inverse relationship
etween NT-proBNP levels and renal function was still
ignificant, although somewhat less robust (r  0.33; p 
.001), suggesting a potentially lesser impact of renal
unction on NT-proBNP levels in the setting of acute CHF.
mong the 209 patients with acute CHF, log-transformed
NP levels were inversely correlated with GFR and in-
reased significantly with decreasing renal function, al-
hough to a slightly lesser degree than NT-proBNP (r 
0.18; p  0.02).
actors influencing NT-proBNP values. In multivariable
inear regression analysis, after adjusting for relevant covari-
tes, the independent predictors of log-transformed NT-
enal Function
Glomerular Filtration Rate (ml/min/1.73 m2)
30–59
n  188)
60–89
(n  226)
>90
(n  166)
p
Value
.1  12.4 60.7  15.7 51.3  15.7 0.001
52% 47% 45% 0.002
44% 18% 6% 0.001
20% 10% 7% 0.001
24% 10% 5% 0.001
9% 5% 2% 0.001
62% 50% 31% 0.001
49% 23% 12% 0.001
.15  .55 0.21  .48 0.37  .80 0.31
.47  .33 0.97  .16 0.75  .14 0.001
61% 25% 15% 0.001
0.001
15% 16% 8%
33% 40% 36%
52% 44% 56%
ation.by R
(
73
0
1roBNP values included age (categorized by decade; p 
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Renal Function and Natriuretic Peptides January 3, 2006:91–7.001), previous CHF (p  0.02), previous cardiomyopathy
p  0.001), New York Heart Association heart failure
unctional classification (p  0.008), atrial fibrillation at
resentation (p  0.02), and GFR (p  0.001). In the
resence of all of the independent predictors identified,
FR remained significantly inversely associated with
lasma natriuretic peptide levels, both in subjects with and
hose without acute CHF. The adjusted beta coefficients
rom multivariable linear regression results examining the
hange in log-transformed NT-proBNP levels associated
ith an increase of 1 ml/min/1.73 m2 in the GFR were
ignificant in the group as a whole (adjusted  coefficient 
0.01; p  0.001), those without acute CHF (adjusted 
oefficient0.006; p 0.01), and those with acute CHF
adjusted  coefficient  0.015; p  0.001).
ssessment of NT-proBNP, renal function, and ROC
nalysis. Among those with a GFR 60 ml/min/1.73 m2
n  393), the area under the ROC curve (Fig. 3) was 0.95
p  0.001), indicating extremely high sensitivity and
pecificity of the assay for the detection of acute CHF.
mong patients with a GFR of 60 ml/min/1.73 m2 (n 
06), the assay for NT-proBNP remained sensitive and
pecific, as indicated by the area under the ROC curve of
.88 (p 0.001). The difference between the area under the
OC curves of patients with GFR and60 ml/min/1.73
2 was not statistically significant (p  0.36).
In an effort to better understand the diagnostic perfor-
ance of NT-proBNP in those with moderate versus severe
able 2. Results of Two-Dimensional Echocardiography, Catego
FR Cut Point of 60 ml/min/1.73 m2), and the Presence or Abs
<60
CHF
(n  49)
pical four-chamber view
Left ventricular end-diastolic volume (ml) 101.7  42.3
Left ventricular end-systolic volume (ml) 56.8  32.8
pical two-chamber view
Left ventricular end-diastolic volume (ml) 102.1  41.5
Left ventricular end-systolic volume (ml) 55.9  31.9
eft atrial volume index 38.3  15.4
jection fraction 48.1  15.1
jection fraction 50% 49.0%
eft ventricular mass index 106.7  37.1
eft ventricular hypertrophy 20.4%
V hypokinesis 16.3%
alvular heart disease
Tricuspid regurgitation severity  moderate 47.0%
Mitral regurgitation severity  moderate 51.0%
iastolic function
Normal 69.4%
Impaired relaxation 6.1%
Pseudonormalized 8.2%
Restrictive 16.3%
V systolic pressure (mm Hg) 50.4  11.9
he number of subjects with available data in each category is indicated.
CHF  congestive heart failure; GFR  glomerular filtration rate; RV  rightenal insufficiency (GFR 60 ml/min/1.73 m2), we divided shose patients with respect to the median GFR in this
ategory (44 ml/min/1.73 m2) and ROC analyses were
erformed in each group. In those subjects with GFR
reater than the median, the area under the ROC curve was
.89 (p 0.0001), whereas in those below the GFR median
n those subjects with moderate or more renal insufficiency,
he area under the ROC curve was 0.86 (p  0.0001); the
ifference between the two ROC curves was not significant
p  0.88).
At the optimal cut point for excluding acute CHF from
he PRIDE study (300 pg/ml), NT-proBNP demonstrated
egative predictive values of 94% and 100% for patients
ith GFR 60 ml/min/1.73 m2 and 60 ml/min/1.73 m2,
espectively. At the optimal cut points for identifying CHF
rom the PRIDE study (of 450 pg/ml for subjects 50
ears of age and 900 pg/ml for subjects 50 years of age),
T-proBNP exhibited a sensitivity of 85% and specificity of
8% for those subjects with a GFR 60 ml/min/1.73 m2.
sing similar cut points for patients with GFR 60
l/min/1.73 m2, the sensitivity was 97% and specificity was
8%. In an effort to identify a diagnostic cut point that
mproved on specificity in patients with moderate-to-severe
enal impairment, ROC analyses suggested that the use of a
ingle cut point of 1,200 pg/ml for patients with GFR 60
l/min/1.73 m2 was optimal, with sensitivity of 89% and
pecificity to 72%; in those with most severe renal insuffi-
iency in the PRIDE study (those below GFR of 44
l/min/1.73 m2), this cut point of 1,200 pg/ml had 92%
With Respect to Renal Function, GFR (Dichotomized With
of CHF
GFR (ml/min/1.73 m2)
<60
Not CHF
(n  12)
>60
CHF
(n  43)
>60
Not CHF
(n  35)
91.1  42.0 111.6  43.8 79.0  23.6
44.8  32.6 69.8  41.0 33.8  14.1
86.7  45.0 114.9  51.5 73.7  26.2
41.7  34.3 70.2  43.2 30.7  15.0
25.1  7.6 43.1  27.6 25.0  9.4
57.0  13.3 42.7  27.6 65.1  22.0
25.0% 55.8% 5.7%
80.7  20.1 101.3  27.9 89.9  25.2
18.2% 11.6% 12.0%
18.2% 31.7% 12.0%
27.3% 30.0% 11.4%
25.0% 31.8% 11.4%
66.7% 73.7% 72.8%
16.7% 2.3% 2.9%
8.3% 4.7% 5.7%
8.3% 9.3% 8.6%
41.1  14.2 46.1  13.5 35.6  12.2
ular.rized
enceensitivity and 70% specificity.
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y 60 days after presentation, 30 subjects (5%) had died.
he association between categories of renal function, NT-
roBNP, and 60-day mortality is detailed in Figure 4.
edian NT-proBNP levels were highest in the subjects
ith a GFR 60 ml/min/1.73 m2 who died by 60 days (n
17; 5,565 pg/ml, interquartile range [IQR]  1,682 to
igure 1. (A) Median amino-terminal pro-brain natriuretic peptide (NT-
roBNP) concentrations across categories of renal function for subjects
ith and without acute congestive heart failure (CHF) in the ProBNP
nvestigation of Dyspnea in the Emergency Department (PRIDE) study.
n addition, (B), the relationship between B-type natriuretic peptide
BNP) concentrations and renal function in the 209 subjects with acute
HF is demonstrated. Boxes denote interquartile ranges, whereas whis-
ers indicate 5th and 95th percentiles. GFR  glomerular filtration rate.3,012); compared with these subjects, NT-proBNP levels
m
sere lower in survivors with GFR 60 ml/min/1.732
2,528 pg/ml, IQR  551 to 8,937, p for difference 
.001). Among those with GFR 60 ml/min/1.73 m2,
imilar patterns of NT-proBNP values were noted, with the
3 subjects dead at 60 days demonstrating significantly
igher NT-proBNP concentrations (1,423 pg/ml [IQR 
91 to 7,572] than 163 pg/ml [IQR  47 to 869] in
urvivors, p for difference  0.001).
In a multivariate analysis examining risk factors for
ortality by 60 days, log-transformed NT-proBNP concen-
rations were the strongest predictor of short-term death
nd remained so even with the inclusion of GFR into the
odel (hazard ratio 1.57; 95% confidence interval 1.2 to 2.0;
 0.0004). Importantly, among those with a GFR 60
l/min/1.73 m2, the prognostic ramifications of NT-
igure 2. Relationship between renal function, expressed as glomerular
ltration rate (GFR), and amino-terminal pro-brain natriuretic peptide
NT-proBNP) results in the entire ProBNP Investigation of Dyspnea in
he Emergency Department (PRIDE) study cohort of 599 subjects.
igure 3. Receiver-operating characteristic curves comparing the perfor-
ance of amino-terminal pro-brain natriuretic peptide for the diagnosis of
cute congestive heart failure in breathless subjects with normal-to-mild
enal insufficiency (glomerular filtration rate [GFR] 60 ml/min/1.73 m2,
 393) versus moderate-to-severely impaired renal function (GFR 60
2l/min/1.73 m , n  206). The difference between the two curves was not
tatistically significant (p  0.34). AUC  area under the curve.
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Renal Function and Natriuretic Peptides January 3, 2006:91–7roBNP concentrations remained significant (hazard ratio
.61; 95% confidence interval 1.14 to 2.26; p  0.006).
ISCUSSION
mong our patients in the PRIDE study, a high coinci-
ence of cardiac and renal insufficiencies (in the form of
HF and CKD, respectively) was present. This intersection
etween cardiac and renal disease has been referred to as the
cardio-renal” interaction (4–8) and has significant impli-
ations for the use of natriuretic peptide assays for the
valuation of patients with CKD because these sensitive
arkers are affected both by structural heart disease—
revalent in patients with CKD in the absence of symp-
omatic CHF (23)—as well as possibly because of their
educed clearance in the setting of renal dysfunction.
The difference between the effects of CKD on NT-
roBNP and BNP levels is controversial. McCullough et al.
17) previously reported an analysis from the Breathing Not
roperly Multinational Study, in which BNP levels were
ound to be related to renal function in patients both with
nd without acute CHF. In our study, NT-proBNP con-
entrations appeared to be more affected than BNP by renal
unction; however, the relationship between NT-proBNP
evels and renal function was much more modest than had
een previously suggested (18,21); as well, the performance
f NT-proBNP was comparable with that reported for
NP: in ROC analyses, we demonstrated an area under the
OC curve for NT-proBNP of 0.88 in analyses among
atients with moderate or worse renal insufficiency, and in
hose with the most severe renal insufficiency in the PRIDE
tudy, the area under the ROC curve remained 0.86.
mong patients with similar renal function in the Breathing
igure 4. The relationship between median amino-terminal pro-brain
atriuretic peptide (NT-proBNP levels), glomerular filtration rate (GFR),
nd 60-day mortality. Boxes denote interquartile ranges, whereas whiskers
ndicate 5th and 95th percentiles.ot Properly Study (17), ROC analyses for BNP demon- mtrated an area under the curve range of 0.81 to 0.86,
epending on severity of renal function impairment. Impor-
antly, at an optimal cut point (of 1,200 pg/ml) for those
ith moderate-to-severe renal insufficiency, NT-proBNP
ad a specificity that compared favorably with results for
NP (24). Thus, despite previous suggestions (18,21), at
ptimal cut points, it is inaccurate to state that decreasing
pecificity for acute CHF due to worsening renal insuffi-
iency is an issue unique to NT-proBNP; irrespective of
enal function, our data strongly support the value of
T-proBNP testing for dyspneic patients for diagnosis and
rognosis.
The current challenge is to ascertain the mechanism of
elationship between NT-proBNP levels and renal function.
he clearance of NT-proBNP in human subjects is not well
nderstood, but small amounts of intact NT-proBNP may
e recovered in urine (25), suggesting a degree of renal
ependence on clearance. Among patients requiring hemo-
ialysis, NT-proBNP levels are markedly elevated
7,20,26–29). Thus, renal clearance is likely one mode of
emoval of NT-proBNP from the circulation, and the more
levated levels of NT-proBNP that were detected in our
atients with CKD may simply reflect decreased clearance.
owever, the wide variety of NT-proBNP levels among
atients with CKD in the PRIDE study suggests that
educed clearance is only one mechanism of the elevation in
T-proBNP levels in such patients.
The concurrence of common risk factors for CHF, the
igh degree of prevalent or incident CHF in those with
KD, expanded plasma volumes in those with CKD, and
he high prevalence of structural and functional cardiac
bnormalities among those with renal insufficiency in ours
nd other studies (26,27,29) suggest that the elevated
T-proBNP levels noted among our subjects with poorer
enal function likely reflect incident and prevalent structural
eart disease. Lending further support to this concept, we
emonstrated NT-proBNP as the strongest risk factor for
eath within 60 days of presentation, maintaining its
rognostic value regardless of renal function.
tudy limitations. That subjects with serum creatinine
2.5 mg/dl were excluded from the PRIDE study is a
imitation of our study because the exclusion of those with
evere renal failure might limit the application of our results
o the everyday population of patients with dyspnea in the
D. This is unlikely, however, as it has been reported that
he majority of patients in the ED with CHF have a GFR
etween 30 and 90 ml/min/1.73 m2 (30), as in our study.
urther, despite the creatinine exclusion criterion, 38% of
ubjects in the PRIDE study had a GFR 60 ml/min/1.73
2, a comparable distribution of subjects with moderate-
o-severe renal insufficiency as in the Breathing Not Prop-
rly Multinational study of BNP (19). Finally, among 6,598
ubjects presenting with acute CHF in the EuroHeart
ailure survey (which did not have a creatinine exclusion),
ore than 90% had a serum creatinine 2.5 mg/dl (31).
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opulation presenting to the ED.
onclusions. In summary, we found a significant inverse
elationship between renal function and NT-proBNP values
n dyspneic patients with and without acute CHF. We
uggest this inverse relationship between NT-proBNP and
FR is not explainable solely on the basis of reduced
learance and more likely reflects the presence of underlying
tructural heart disease and increased plasma volume in
atients with CKD. Although the perception is that the
erformance of NT-proBNP as a diagnostic marker is more
dversely affected by renal function than BNP (18,21), we
ound that NT-proBNP was useful for both diagnosing or
xcluding acute CHF across a wide spectrum of renal
unction (with results comparable with those reported for
NP) and that regardless of renal function maintained its
alue for prognostication of short-term mortality in CHF.
e therefore conclude that at optimal cut points, even in
he presence of impaired renal function, NT-proBNP mea-
urement is a valuable tool for the diagnostic and prognostic
valuation of dyspneic patients.
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